Yoshiro Naito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshiro Naito has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Tohru Masuyama
Department of Cardiovascular and Renal Medicine, School of Medicine, Hyogo Medical University, Nishinomiya, Japan; Nishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan
50 shared publicationsHisashi Sawada
Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Lexington, USA
27 shared publicationsAkiyo Eguchi
Hyogo Medical University
23 shared publicationsMasaharu Ishihara
Department of Cardiovascular and Renal Medicine, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
22 shared publicationsToshihiro Iwasaku
Cardiovascular Division, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan
20 shared publicationsMasanori Asakura
Department of Cardiovascular and Renal Medicine, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
19 shared publications
Latest Publications
- Open Access
- 16 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7307
Integrin α7-Driven Senescence-Associated Follicular Helper T Cell Adhesion Induces Tertiary Lymphoid Structures in Nishiura Mice
Senescence-associated follicular helper T (SA-Tfh) cells contribute to tertiary lymphoid structure (TLS) formation in autoimmune diseases, yet the mechanisms guiding their localization to glandular niches remain unclear. In the Nishiura (NI) Sjögren’s disease (SjD) mouse model, we demonstrated that mouse SA-Tfh (mSA-Tfh; CD4+/PD-1+/CD153+) cells form TLSs specifically within the submandibular gland niche. We identified integrin α7 (ITGα7) expression in mSA-Tfh cells and examined its functional role. Adhesion of mSA-Tfh cells to laminin (LAM) α2/α3/α4 was inhibited by anti-ITGα7 IgG (E-2), and ITGα7-deficient mSA-Tfh cells had reduced adhesion to LAMα1/α2 compared with LAMα3/α4/α5. Osteopontin production by mSA-Tfh cells, either alone or via interactions with mB220+/PD-1+ cells, was suppressed by E-2, anti-LAMα4 IgG, and ITGα7 deficiency. In female NI mice, E-2 administration at 24 weeks reduced Greenspan grade 4 TLSs at 28 weeks by decreasing ITGα7+/CD153+ cell accumulation. mSA-Tfh infiltration into aged C57BL/6 mice was similarly diminished by ITGα7 or LAMα4 deficiency. In human SjD cohorts, ITGα7 expression positively correlated with CD153 expression (R2 = 0.41) in peripheral lymphocytes and with LAMα4 expression (R2 = 0.35) in salivary gland vasculature and ducts. These findings suggest that circulating ITGα7+ SA-Tfh cells adhere to the LAMα4+ glandular niche to promote TLS formation in SjD.
- 16 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7307
Open AccessIntegrin α7-Driven Senescence-Associated Follicular Helper T Cell Adhesion Induces Tertiary Lymphoid Structures in Nishiura Mice
Senescence-associated follicular helper T (SA-Tfh) cells contribute to tertiary lymphoid structure (TLS) formation in autoimmune diseases, yet the mechanisms guiding their localization to glandular niches remain unclear. In the Nishiura (NI) Sjögren’s disease (SjD) mouse model, we demonstrated that mouse SA-Tfh (mSA-Tfh; CD4+/PD-1+/CD153+) cells form TLSs specifically within the submandibular gland niche. We identified integrin α7 (ITGα7) expression in mSA-Tfh cells and examined its functional role. Adhesion of mSA-Tfh cells to laminin (LAM) α2/α3/α4 was inhibited by anti-ITGα7 IgG (E-2), and ITGα7-deficient mSA-Tfh cells had reduced adhesion to LAMα1/α2 compared with LAMα3/α4/α5. Osteopontin production by mSA-Tfh cells, either alone or via interactions with mB220+/PD-1+ cells, was suppressed by E-2, anti-LAMα4 IgG, and ITGα7 deficiency. In female NI mice, E-2 administration at 24 weeks reduced Greenspan grade 4 TLSs at 28 weeks by decreasing ITGα7+/CD153+ cell accumulation. mSA-Tfh infiltration into aged C57BL/6 mice was similarly diminished by ITGα7 or LAMα4 deficiency. In human SjD cohorts, ITGα7 expression positively correlated with CD153 expression (R2 = 0.41) in peripheral lymphocytes and with LAMα4 expression (R2 = 0.35) in salivary gland vasculature and ducts. These findings suggest that circulating ITGα7+ SA-Tfh cells adhere to the LAMα4+ glandular niche to promote TLS formation in SjD.
- Open Access
- 12 December 2025
- Published by Elsevier in Atherosclerosis Plus
- Vol. 63, 14-18
Heterozygous transferrin receptor 1 deletion reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice
- 12 December 2025
- Published by Elsevier in Atherosclerosis Plus
- Vol. 63, 14-18
Open AccessHeterozygous transferrin receptor 1 deletion reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice
- Open Access
- 19 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e040320
Atrial Natriuretic Peptide at Discharge as a Predictive Marker for Early Rehospitalization in Patients With Heart Failure With Preserved Ejection Fraction
Background: Patients admitted for heart failure with preserved ejection fraction (HFpEF) are at risk for rehospitalization, especially within 90 days post discharge. NPs (natriuretic peptides), namely ANP (atrial NP) and BNP (brain NP), are important biomarkers in HF management, but their role in predicting early rehospitalization in patients with HFpEF remains unclear. Methods: A retrospective analysis was conducted on 147 patients with HFpEF hospitalized for HF. ANP and BNP levels were measured at admission and discharge. Rehospitalization events were analyzed to evaluate the prognostic impact of NPs. Results: Among 147 patients, 47 (32.0%) were rehospitalized within 1 year, including 22 (15.0%) within the 90 days postdischarge. Elevated discharge ANP (>113 pg/mL) was significantly associated with early rehospitalization (log‐rank P =0.0053). This was confirmed in Cox models using log‐transformed standardized ANP (hazard ratio [HR] per SD, 2.01 [95% CI, 1.34–3.02]; P =0.0008) whereas discharge BNP levels showed weaker predictive value. Discharge ANP remained a significant predictor even after adjusting for age, body mass index, or estimated glomerular filtration ratio, whereas discharge BNP did not. Interaction analysis revealed that ANP has stronger prognostic association in patients with lower left atrial volume index ( P for interaction=0.034) but not with atrial fibrillation status ( P for interaction=0.217), despite a numerically stronger association in patients without atrial fibrillation. Conclusions: Discharge ANP was a robust predictor of early rehospitalization in patients with HFpEF. These findings suggest that incorporating ANP measurements into postdischarge management may improve risk stratification to reduce early rehospitalization in patients with HFpEF.
- 19 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e040320
Open AccessAtrial Natriuretic Peptide at Discharge as a Predictive Marker for Early Rehospitalization in Patients With Heart Failure With Preserved Ejection Fraction
Background: Patients admitted for heart failure with preserved ejection fraction (HFpEF) are at risk for rehospitalization, especially within 90 days post discharge. NPs (natriuretic peptides), namely ANP (atrial NP) and BNP (brain NP), are important biomarkers in HF management, but their role in predicting early rehospitalization in patients with HFpEF remains unclear. Methods: A retrospective analysis was conducted on 147 patients with HFpEF hospitalized for HF. ANP and BNP levels were measured at admission and discharge. Rehospitalization events were analyzed to evaluate the prognostic impact of NPs. Results: Among 147 patients, 47 (32.0%) were rehospitalized within 1 year, including 22 (15.0%) within the 90 days postdischarge. Elevated discharge ANP (>113 pg/mL) was significantly associated with early rehospitalization (log‐rank P =0.0053). This was confirmed in Cox models using log‐transformed standardized ANP (hazard ratio [HR] per SD, 2.01 [95% CI, 1.34–3.02]; P =0.0008) whereas discharge BNP levels showed weaker predictive value. Discharge ANP remained a significant predictor even after adjusting for age, body mass index, or estimated glomerular filtration ratio, whereas discharge BNP did not. Interaction analysis revealed that ANP has stronger prognostic association in patients with lower left atrial volume index ( P for interaction=0.034) but not with atrial fibrillation status ( P for interaction=0.217), despite a numerically stronger association in patients without atrial fibrillation. Conclusions: Discharge ANP was a robust predictor of early rehospitalization in patients with HFpEF. These findings suggest that incorporating ANP measurements into postdischarge management may improve risk stratification to reduce early rehospitalization in patients with HFpEF.
- Open Access
- 9 June 2025
- Published by Springer Nature in Hypertension Research
- Vol. 48 (8) , 1-6
Transferrin receptor 1 deficiency in smooth muscle cells attenuates vascular remodeling in hypertensive mice
Transferrin receptor 1 (TfR1), a crucial cellular iron receptor, has a variety of biological functions. We have previously reported that TfR1 abundance increases in the aortic media of hypertensive rat models. However, its role in vascular diseases remains unknown. In the present study, we generated smooth muscle cell (SMC)-specific TfR1 deficient mice and examined the impact of its deletion in mouse models of hypertension induced by angiotensin II or deoxycorticosterone acetate/salt administration. SMC-specific TfR1 deletion attenuated medial thickening and elastin fragmentation in both mouse models of hypertension. These results indicate that TfR1 in SMCs exerts a role in vascular remodeling in hypertension.
- 9 June 2025
- Published by Springer Nature in Hypertension Research
- Vol. 48 (8) , 1-6
Open AccessTransferrin receptor 1 deficiency in smooth muscle cells attenuates vascular remodeling in hypertensive mice
Transferrin receptor 1 (TfR1), a crucial cellular iron receptor, has a variety of biological functions. We have previously reported that TfR1 abundance increases in the aortic media of hypertensive rat models. However, its role in vascular diseases remains unknown. In the present study, we generated smooth muscle cell (SMC)-specific TfR1 deficient mice and examined the impact of its deletion in mouse models of hypertension induced by angiotensin II or deoxycorticosterone acetate/salt administration. SMC-specific TfR1 deletion attenuated medial thickening and elastin fragmentation in both mouse models of hypertension. These results indicate that TfR1 in SMCs exerts a role in vascular remodeling in hypertension.
- Open Access
- 21 May 2025
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 204, 35-39
Anti-transferrin receptor 1 antibody reduces angiotensin II-induced vascular remodeling
- 21 May 2025
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 204, 35-39
Open AccessAnti-transferrin receptor 1 antibody reduces angiotensin II-induced vascular remodeling
- 27 November 2023
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 42 (3) , 497-505
Hypoxia-inducible factor-prolyl hydroxylase inhibitor Roxadustat (FG-4592) reduces renal fibrosis in Dahl salt-sensitive rats
Objective: Although hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors have been developed for the treatment of renal anemia, their effects on cardiac and renal dysfunction remain unknown. We previously reported on Dahl salt-sensitive rats, in a rat model of salt-sensitive hypertension, that exhibited anemia and impaired expression of duodenal iron transporters after the development of hypertensive cardiac and renal dysfunction. Therefore, we investigated the effects of Roxadustat (FG-4592), an HIF-PH inhibitor, on anemia, iron regulation, and cardiac and renal dysfunction in Dahl salt-sensitive rats. Methods: Six-week-old male Dahl salt-sensitive rats were fed a normal or high-salt diet for 8 weeks. A further subset of Dahl salt-sensitive rats, that were fed a high-salt diet, was administered Roxadustat for 8 weeks. Results: Dahl salt-sensitive rats fed a high-salt diet developed hypertension, cardiac and renal dysfunction, and anemia after 8 weeks of feeding. Roxadustat increased hemoglobin and serum erythropoietin levels in Dahl salt-sensitive rats fed a high-salt diet. With regard to the iron-regulating system, Roxadustat lowered hepatic hepcidin gene expression and increased the gene expression of duodenal iron transporters, such as cytochrome b and divalent metal transporter 1, in Dahl salt-sensitive rats fed a high-salt diet. Roxadustat did not affect the development of hypertension and cardiac hypertrophy in Dahl salt-sensitive rats with a high-salt diet; however, Roxadustat treatment attenuated renal fibrosis in these rats. Conclusions: Roxadustat ameliorated anemia with affecting the gene expression of the iron-regulating system, and did not affect cardiac hypertrophy but attenuated renal fibrosis in Dahl salt-sensitive rats fed a high-salt diet.
- 27 November 2023
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 42 (3) , 497-505
Hypoxia-inducible factor-prolyl hydroxylase inhibitor Roxadustat (FG-4592) reduces renal fibrosis in Dahl salt-sensitive rats
Objective: Although hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors have been developed for the treatment of renal anemia, their effects on cardiac and renal dysfunction remain unknown. We previously reported on Dahl salt-sensitive rats, in a rat model of salt-sensitive hypertension, that exhibited anemia and impaired expression of duodenal iron transporters after the development of hypertensive cardiac and renal dysfunction. Therefore, we investigated the effects of Roxadustat (FG-4592), an HIF-PH inhibitor, on anemia, iron regulation, and cardiac and renal dysfunction in Dahl salt-sensitive rats. Methods: Six-week-old male Dahl salt-sensitive rats were fed a normal or high-salt diet for 8 weeks. A further subset of Dahl salt-sensitive rats, that were fed a high-salt diet, was administered Roxadustat for 8 weeks. Results: Dahl salt-sensitive rats fed a high-salt diet developed hypertension, cardiac and renal dysfunction, and anemia after 8 weeks of feeding. Roxadustat increased hemoglobin and serum erythropoietin levels in Dahl salt-sensitive rats fed a high-salt diet. With regard to the iron-regulating system, Roxadustat lowered hepatic hepcidin gene expression and increased the gene expression of duodenal iron transporters, such as cytochrome b and divalent metal transporter 1, in Dahl salt-sensitive rats fed a high-salt diet. Roxadustat did not affect the development of hypertension and cardiac hypertrophy in Dahl salt-sensitive rats with a high-salt diet; however, Roxadustat treatment attenuated renal fibrosis in these rats. Conclusions: Roxadustat ameliorated anemia with affecting the gene expression of the iron-regulating system, and did not affect cardiac hypertrophy but attenuated renal fibrosis in Dahl salt-sensitive rats fed a high-salt diet.
- Open Access
- 6 October 2023
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 35, 100332
Reticulocyte hemoglobin equivalent is an easily applicable marker for detecting iron deficiency in patients with acute decompensated heart failure
- 6 October 2023
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 35, 100332
Open AccessReticulocyte hemoglobin equivalent is an easily applicable marker for detecting iron deficiency in patients with acute decompensated heart failure
- Open Access
- 17 August 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
Clinical utility of reticulocyte hemoglobin equivalent in patients with heart failure
Anemia and iron deficiency (ID) are common in patients with heart failure (HF) and intravenous (IV) administration of iron to patients hospitalized for decompensated HF with ID improves outcome. The diagnosis of ID in routine practice is based on serum ferritin and transferrin saturation (TSAT) but both have limitations; alternatives should be considered. Reticulocyte hemoglobin equivalent (Ret-He) reflects iron content in reticulocytes but its clinical utility in patients with HF remains uncertain. We prospectively enrolled 142 patients hospitalized for decompensated HF. Sixty five percent had ID as defined in current international guidelines. Ret-He was directly correlated with serum iron and ferritin concentrations and with TSAT. There was a poor relationship between quartile of Ret-He and HF hospitalization or death but increases or decreases in Ret-He between admission and discharge were associated with a worse outcome. The clinical utility of Ret-He for identifying ID and predicting response to IV iron and prognosis for patients with HF requires further investigation.
- 17 August 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
Open AccessClinical utility of reticulocyte hemoglobin equivalent in patients with heart failure
Anemia and iron deficiency (ID) are common in patients with heart failure (HF) and intravenous (IV) administration of iron to patients hospitalized for decompensated HF with ID improves outcome. The diagnosis of ID in routine practice is based on serum ferritin and transferrin saturation (TSAT) but both have limitations; alternatives should be considered. Reticulocyte hemoglobin equivalent (Ret-He) reflects iron content in reticulocytes but its clinical utility in patients with HF remains uncertain. We prospectively enrolled 142 patients hospitalized for decompensated HF. Sixty five percent had ID as defined in current international guidelines. Ret-He was directly correlated with serum iron and ferritin concentrations and with TSAT. There was a poor relationship between quartile of Ret-He and HF hospitalization or death but increases or decreases in Ret-He between admission and discharge were associated with a worse outcome. The clinical utility of Ret-He for identifying ID and predicting response to IV iron and prognosis for patients with HF requires further investigation.
- 1 July 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (7) , e009034
Iron Deficiency Induces Heart Failure With Ectopic Cardiac Calcification in Mice With Metabolic Syndrome
- 1 July 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (7) , e009034
Iron Deficiency Induces Heart Failure With Ectopic Cardiac Calcification in Mice With Metabolic Syndrome